Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus

J Hypertens. 2005 Feb;23(2):435-44. doi: 10.1097/00004872-200502000-00027.

Abstract

Objective: Circulating adhesion molecules may have a prognostic significance as markers of endothelial damage. Drugs which inhibit the renin-angiotensin system may be effective in reducing circulating or tissue adhesion molecules, albeit data available are scarce. The aim of the study was to investigate the effects of an angiotensin-converting enzyme (ACE) inhibitor, enalapril and a highly selective angiotensin receptor blocker, candesartan cilexetil, on circulating adhesion molecules in a large sample of patients with non-insulin-dependent diabetes mellitus (NIDDM). The study was comparative, multicenter, randomized and double blind, with two parallel groups.

Patients and methods: NIDDM patients with a diagnosis of mild (grade 1) essential hypertension were included in the study, at the end of a 2-week placebo run-in period. The primary end-point of the study was to evaluate changes of intercellular adhesion molecule-1 (ICAM-1) plasma levels during treatment. The secondary end-points were: changes in vascular cells adhesion molecule-1 (VCAM-1), von Willebrand factor (vWF), fibrinogen and plasminogen activator inhibitor-1 (PAI-1) circulating levels and of urinary albumin excretion rate (AER) as well; 129 patients were randomized: 66 in the candesartan group and 63 in the enalapril group, 118 of them completed the scheduled 24-week treatment period.

Results: Candesartan and enalapril equally reduced circulating level of ICAM-1 and exerted comparable effects on changes of other adhesion molecules and coagulation factors. A similar blood pressure-lowering effect was observed with the two drugs (candesartan: from 148/90 +/- 11/8 to 132/82 +/- 12/7 mmHg, P < 0.01, enalapril: from 148/91 +/- 12/8 to 131/85 +/- 14/6 mmHg, P < 0.01). Candesartan was more effective than enalapril in the reduction of albuminuria (P < 0.05 between treatments), although urinary protein excretion can be considered normal in the majority of patients. The two drugs were comparable in terms of adverse events reported.

Conclusion: Candesartan and enalapril showed similar effects on blood pressure and on circulating adhesion molecules. In this study urinary protein excretion was reduced more by candesartan.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Albuminuria / drug therapy
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Arteriosclerosis / drug therapy*
  • Benzimidazoles / adverse effects
  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use*
  • Biomarkers / blood
  • Biphenyl Compounds / adverse effects
  • Biphenyl Compounds / pharmacology
  • Biphenyl Compounds / therapeutic use*
  • Blood Pressure / drug effects
  • Diabetes Mellitus, Type 2 / complications*
  • Double-Blind Method
  • Enalapril / adverse effects
  • Enalapril / pharmacology
  • Enalapril / therapeutic use*
  • Female
  • Fibrinogen / analysis
  • Fibrinogen / drug effects
  • Humans
  • Hypertension / drug therapy*
  • Intercellular Adhesion Molecule-1 / blood
  • Intercellular Adhesion Molecule-1 / drug effects
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / blood
  • Tetrazoles / adverse effects
  • Tetrazoles / pharmacology
  • Tetrazoles / therapeutic use*
  • Vascular Cell Adhesion Molecule-1 / blood
  • Vascular Cell Adhesion Molecule-1 / drug effects
  • von Willebrand Factor / analysis
  • von Willebrand Factor / drug effects

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Benzimidazoles
  • Biomarkers
  • Biphenyl Compounds
  • Plasminogen Activator Inhibitor 1
  • Tetrazoles
  • Vascular Cell Adhesion Molecule-1
  • von Willebrand Factor
  • Intercellular Adhesion Molecule-1
  • Enalapril
  • Fibrinogen
  • candesartan cilexetil